Immunotherapy choices in inflammatory neuromuscular diseases
| Steroids | Intravenous Ig/SCIg | AZA | MTX | MMF | CYC | PLEX | |
| GBS | No | 1 | No | No | No | No | 1 |
| CIDP | 1 | 1 | 2 | No | 3 | 3 | 3 |
| MMN | No | 1 | No | No | No | 2 | No |
| Vasculitic neuropathy | 1 | No | 2 | 3 | * | 1 | No |
| Polymyositis | 1 | 2 | 2 | 2 | 3 | * | * |
| Dermatomyositis | 1 | 2 | 2 | 2 | 3 | * | * |
| Myasthenia gravis | 1 | cr>m | 2 (m) | 3 (m) | 2 (m) | * | 1 |
1 indicates first-line response, 2 indicates second-line response and 3 indicates third-line response.
*May consider in individual cases.
AZA, azathioprine; CIDP, chronic inflammatory demyelinating polyneuropathy; cr, treatment of myasthenic crisis; CYC, cyclophosphamide; GBS, Guillain-Barré syndrome; m, maintenance treatment; MMF, mycophenolate mofetil; MMN, multifocal motor neuropathy; MTX, methotrexate; No, not recommended; PLEX, plasma exchange; SCIg, subcutaneous immunoglobulin.